Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 19

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 19
---
 the
pharmaceutical industry qualify her to be a member of the Board.

Dr. Stephen Toovey is one of our
directors since July 11, 2023 and is an infectious and tropical disease physician. Dr. Toovey has worked in the pharmaceutical industry
and academia in both developed and developing countries, and currently specializes in the research of influenza and other respiratory
viruses, malaria, rabies and the neurological aspects of infectious diseases. He is currently the Chief Executive Officer of Pegasus,
a medical and scientific services company and has held that position since 2008. Dr. Toovey also advises a number of pharmaceutical companies
and biotech organizations on infection and immunology related matters, from translation through Phase IV, and founded numerous pharmaceutical
and pharma-related companies, with the most recent being the co-founding of Ark Biosciences in 2014. Dr. Toovey served as Chief Medical
Officer of Ark Biosciences from 2014 until 2020. In addition, he held a teaching and clinical post at the Royal Free and University College
Medical School in London, United Kingdom, Academic Centre for Travel Medicine and Vaccines, World Health Organization Collaborating Center,
appointed in 2008. He has been editor of the journal Travel Medicine and Infectious Disease since its foundation in 2003. Dr. Toovey has
authored over 100 publications in peer reviewed medical journals, contributed to a number of textbooks and has presented at over 50 scientific
meetings. Dr. Toovey received his PhD from the University of Ghent. The Board concluded that Dr. Toovey’s background and leadership
experiences in the pharmaceutical industry and academia qualify him to be a member of the Board.

Paul Field is one of our directors
since July 11, 2023. Paul has over 30 years of business development experience across a range of disease areas, and a deep network in
the global biopharmaceutical industry. He is currently a corporate advisor at Imunexus since 2020, Marinova since 2018, and GARDP (Switzerland)
since 2018. He was until recently the Australian representative of FIND (Switzerland) from 2018 to 2021 and a business development advisor
to the drug discovery company Biocurate from 2018 to 2020. Paul was previously the life sciences specialist at Austrade from 2014 to 2018,
the Australian Government’s